Form 4: Nektar Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Roy A Whitfield, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.
Summary
- Grant/award: acquired 2,000 Common Stock on September 23, 2026; holds 16,417 after (Direct).
- Grant/award: acquired 4,000 Stock Option on September 23, 2026; holds 4,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Roy A Whitfield — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Grant/award | Common Stock | 2,000 | — | — | 16,417 |
| 2026-09-23 | Grant/award | Stock Option | 4,000 | — | — | 4,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Grant/award (2,000 shares) |
| 2026-09-23 | Grant/award (4,000 shares) |
Keywords
insider transaction, Form 4, NKTR, NEKTAR THERAPEUTICS, neutral, Roy A Whitfield
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.